Can 'double blockbuster' strengthen Amgen's backbone? (vol 26, pg 361, 2008)

被引:0
作者
Sheridan, Cormac
机构
关键词
D O I
10.1038/nbt0808-947c
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nat. Biotechnol. 26, 361–363 (2008); published online 7 April 2008; corrected after print 7 August 2008 In the version of this article initially published, in Table 1, page 362, Protelos was wrongly cited as strontium malonate; in fact, Protelos is the current brand name of strontium ranelate. Unlike strontium malonate, strontium ranelate is approved by the European Medicines Evaluation Agency (EMEA) for the treatment of post-menopausal osteoporosis and has been shown in published clinical trials to decrease the risk of vertebral, nonvertebral and hip fractures in post-menopausal osteoporosis.
引用
收藏
页码:947 / 947
页数:1
相关论文
共 1 条